Clinical Trial Update: Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating azacitidine with abatacept for relapsed or refractory T-cell lymphomas is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Angioimmunoblastic T-cell Lymphoma
• Monomorphic Epitheliotropic Intestinal T-cell Lymphoma
• Peripheral T-cell Lymphoma
• T-cell Leukemia Lymphoma
• T-cell Lymphoma

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Abatacept (abatacept)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Lymphoma, T Cell, Peripheral, T-cell Lymphoma | Phase 1 | Status: RECRUITING